Zacks: Cantel Medical Corp. (CMD) Receives Average Rating of “Buy” from Analysts

Shares of Cantel Medical Corp. (NYSE:CMD) have been given an average broker rating score of 2.25 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. Cantel Medical’s rating score has improved by 10% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a twelve-month consensus price objective of $120.00 for the company and are predicting that the company will post $0.58 EPS for the current quarter, according to Zacks. Zacks has also assigned Cantel Medical an industry rank of 170 out of 265 based on the ratings given to related companies.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMD. UBS Asset Management Americas Inc. purchased a new position in Cantel Medical in the second quarter valued at $1,648,000. FMR LLC purchased a new position in Cantel Medical in the second quarter valued at $53,614,000. California Public Employees Retirement System purchased a new position in Cantel Medical in the second quarter valued at $5,423,000. Advisor Group Inc. purchased a new position in Cantel Medical in the second quarter valued at $249,000. Finally, Parametric Portfolio Associates LLC purchased a new position in Cantel Medical in the second quarter valued at $4,820,000. 85.37% of the stock is owned by institutional investors.

Cantel Medical (CMD) opened at $109.78 on Tuesday. The company has a current ratio of 2.44, a quick ratio of 1.48 and a debt-to-equity ratio of 0.31. Cantel Medical has a fifty-two week low of $69.21 and a fifty-two week high of $116.79. The stock has a market cap of $4,457.76, a price-to-earnings ratio of 60.65 and a beta of 1.26.

Cantel Medical (NYSE:CMD) last released its quarterly earnings data on Thursday, December 7th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.05. Cantel Medical had a net margin of 9.50% and a return on equity of 17.42%. analysts forecast that Cantel Medical will post 2.35 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/zacks-cantel-medical-corp-cmd-receives-average-rating-of-buy-from-analysts.html.

About Cantel Medical

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Get a free copy of the Zacks research report on Cantel Medical (CMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply